The US FDA has approved veligrotug-vvze (Lumvoa) for the treatment of thyroid eye disease (TED), irrespective of disease activity or duration. Veligrotug is an insulin-like growth factor-1 receptor inhibitor, although its precise mechanism of action in patients with TED has not been fully established. Clinical evidence The approval is supported by findings from two clinical trials involving a total of 301 patients. In Study 1, which enrolled patients with active TED, 70% of patients treated with veligrotug achieved a proptosis response, defined as a reduction of at least 2 mm in proptosis, at week 15 compared with 5% of those receiving placebo.
The mean change in proptosis from baseline at week 15 was -2.9 mm with veligrotug versus -0.5 mm with placebo. Additionally, 59% of patients in the veligrotug group achieved a diplopia response compared with 20% in the placebo group. Diplopia…
